Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Abstract

We review clinical trials of squamous cell carcinoma of the head and neck (SCCHN) to address the current and potential uses of cetuximab (CTX). PubMed was reviewed to identify papers published between 2010 and 2016. The search terms used were “cetuximab” and “head and neck cancer.” A total of 634 articles were identified. Phase II or III studies with CTX in patients with advanced SCCHN without treatment or with recurrent/metastatic tumors were selected. Forty-six registries were obtained. Information was critically reviewed and relevant information presented. As definitive treatment of advanced squamous cells carcinomas and as palliative treatment of recurrent/metastatic disease, CTX alone or associated with chemotherapy and/or radiotherapy is an alternative to chemoradiotherapy because of its distinct and favorable toxicity profile.

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib

“…The patient had already undergone chemo-radiotherapy in the past and that any further change in chemotherapy regimen would have low efficiency and would be difficult to tolerate due to the high toxic side effects. Based on limited clinical experience, [5][6][7] cetuximab monotherapy or cetuximab in combination with anlotinib may be effective. He was administered cetuximab (400 mg/m 2 on day 1, every week) and anlotinib (12 mg on day 1-14) in December 2018.…”